secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112977
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics receives Nasdaq delisting determination for non-compliance with stockholders' equity requirement
--------------------------------------------------------------------------------

- Nasdaq notified Iterum on Oct 1, 2024 that it failed to meet terms of extension to comply with minimum $2.5M stockholders' equity requirement.
- Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending hearing conclusion.
- At hearing, Iterum will present a plan to regain compliance; Panel may grant extension up to March 31, 2025.
- Ordinary shares continue trading on Nasdaq Capital Market under symbol ITRM pending hearing process outcome.
- No assurance that Panel will grant extension or that company will ultimately regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024112977/0000950170-24-112977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024112977/itrm-20241001.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer